NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/23/2024
Back to search
Official data from USPTO
ADTHERA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ADTHERA
ST13
US500000097489717Class
9, 40, 42
Filing
97489717
Registration
7362949
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
04/23/2024
Trademark type
Word
Nice classes
9, 40, 42
Filing date
07/05/2022
Registration date
04/23/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/23/2024
Last transaction
04/23/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
24
Owner location
LONDON, GB
Examiner
CANFIELD III, JOSEPH
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ADTHERA BIO LIMITED
Delin Ventures Advisors Limited
Representatives
Jonathan A. Menkes KNOBBE, MARTENS, OLSON & BEAR, LLP
Technical classification
Nice Classes
Class 9Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Downloadable software and software applications used to deliver information and content regarding advanced therapy medicinal products (ATMPs)cell and gene therapy products and services; downloadable software and software applications for use in pharmaceutical manufacturingdrug developmentdelivery of therapies to patients in the fields of advanced therapy medicinal productscell therapy and gene therapy
Class 40
Cell culturecell therapy and gene therapy manufacturing services for others; manufacturing of advanced therapy medicinal products (ATMPs) for others; custom manufacture of therapeutic drugsmedicinescell therapies and gene therapies for others; custom manufacture of cell culture products for others; rental and leasing of cell culturecell therapy and gene therapy manufacturing apparatus; informationadvice and consultancy in relation to all the aforesaid
Class 42
Biotechnology research; design and development of pharmaceutical products in the field of biotechnology; scientific research for medical purposes in the field of cell culturecell therapy and gene therapy; scientific research consultancy in relation to cell culturecell therapygene therapy manufacturing; development of cell culturecell therapy and gene therapy processes for others; scientific research in the nature of conducting clinical trials for others in the field of cell culturecell therapy and gene therapy services; scientific research in the nature of conducting clinical trials for others; pharmaceutical drug development services; rental of scientific apparatus and instruments; development of processes for cell culturecell therapy and gene therapy pharmaceutical manufacturing; development of processes for manufacturing of advanced therapy medicinal products; design and development of scientific cell culturecell therapy and gene therapy equipment and apparatus; design and development of scientific advanced therapy medicinal productspharmaceutical manufacturing equipment and apparatus; software as a service (SaaS) featuring software for pharmaceutical manufacturing and drug development in the field of advanced therapy medicinal productscell therapygene therapy and cell culture; providing temporary use ofonline non-downloadable software and online non-downloadable software platforms for pharmaceutical manufacturing and drug development in the field of advanced therapy medicinal productscell therapygene therapy and cell culture; software as a service (SaaS) featuring software for reviewingpurchasingorderingtrackingdeliveringmonitoring and analysing advanced therapy medicinal productscell therapygene therapy and cell culture products and services; platform as a service featuring computer software platforms for reviewingpurchasingorderingtrackingdeliveringmonitoring and analysing advanced therapy medicinal productscell therapygene therapy and cell culture products and services; providing temporary use of online non-downloadable software and online non-downloadable software platforms for reviewingpurchasingorderingtrackingdeliveringmonitoring and analysing advanced therapy medicinal productscell therapygene therapy and cell culture products and services; providing informationadvice and consultancy in relation to all the aforesaid
Publications
History of USPTO decisions and trademark events.
27 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/23/2024
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
03/17/2024
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
12/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/07/2023
PUBO
PUBLISHED FOR OPPOSITION
11/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/18/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
10/03/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
09/29/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/27/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
08/30/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/30/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
08/30/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/30/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/09/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/02/2023
GNRT
NON-FINAL ACTION E-MAILED
05/02/2023
CNRT
NON-FINAL ACTION WRITTEN
05/02/2023
DOCK
ASSIGNED TO EXAMINER
04/18/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
08/15/2022
ALIE
ASSIGNED TO LIE
08/15/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/25/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
07/08/2022
NWAP
NEW APPLICATION ENTERED
07/08/2022
Continuous trademark protection
Get notified about every new filing that threatens ADTHERA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.